raremaprare-disease reference indexOrphadata 2026-06-23 · HPO 2026-09-01
ORPHA:99976

Adenocarcinoma of the oesophagus and oesophagogastric junction

Synonyms: Adenocarcinoma of the esophagus and the gastroesophageal junction · Esophageal adenocarcinoma and adenocarcinoma of the esophagogastric junction

Type
Disease
Group
Disorder
Inheritance
Not applicable
Age of onset
Adult, Elderly
Status
active

Esophageal adenocarcinoma (EAC) is a sub-type of esophageal carcinoma (EC) affecting the glandular cells of the lower esophagus at the junction with the stomach.

1

Names in Orphadata languages

12 of 12 languages
LangNameSynonyms
enAdenocarcinoma of the oesophagus and oesophagogastric junctionAdenocarcinoma of the esophagus and the gastroesophageal junction · Esophageal adenocarcinoma and adenocarcinoma of the esophagogastric junction
frAdénocarcinome de l'oesophage et de la jonction oesogastrique
deAdenokarzinom der Speiseröhre und des ösophago-gastralen ÜbergangsAdenokarzinom des Ösophagus und des gastroösophagealen Übergangs
esAdenocarcinoma de esófago y de la unión esofagogástricaAdenocarcinoma esofágico y adenocarcinoma de la unión esofagogástrica
itAdenocarcinoma dell'esofago e della giunzione esofago-gastricaAdenocarcinoma dell'esofago e della giunzione gastroesofagea · Adenocarcinoma esofageo e adenocarcinoma della giunzione esofago-gastrica
nlAdenocarcinoom van oesofagus en oesofagogastrische overgangOesofageaal adenocarcinoom en adenocarcinoom van oesofagogastrische overgang · Adenocarcinoom van slokdarm en gastro-oesofageale overgang
ptAdenocarcinoma do esófagoAdenocarcinoma esofágico
plGruczolakorak przełykuGruczolakorak przełyku i połączenia przełykowo-żołądkowego
csAdenokarcinom jícnuEzofageální adenokarcinom
ukАденокарцинома стравоходуАденокарцинома стравоходу
zh食道腺癌食管腺癌
trYemek borusu adenokarsinomuÖzofageal adenokarsinom

Definition in:

2

Cross-references

qualifier = Orphanet mapping relation
SourceCodeQualifierICD relationValidation
OMIM614266NTBTvalidated
ICD-10C15.2BTNTattributedvalidated
ICD-10C15.5BTNTattributedvalidated
ICD-112B70.0Especificvalidated
MONDO0005028Evalidated
MeSHC562730Evalidated
UMLSC0279628Evalidated
MedDRA10030137Evalidated

E exact · NTBT this ORPHAcode is narrower than the target · BTNT broader than the target · ND not decided.

3

Classification

Preferential parent (Orphanet linearisation):

Parents in the classifications (1):

No children.

4

Genes

1 direct
GeneAssociationStatusHGNCEnsemblOMIMLocusNameSource of validation
ERBB2Biomarker tested inAssessedHGNC:3430ENSG0000014173616487017q12erb-b2 receptor tyrosine kinase 227468182[PMID]
5

Prevalence and incidence

28 records
TypeClassValueAreaQualificationValidationSource
Annual incidence1-9 / 100 0003.264 / 100 000EuropeValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Point prevalence1-9 / 100 000—EuropeClass onlyValidated22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[OTHER]
Lifetime Prevalence1-9 / 100 0005.55 / 100 000EuropeValue and classValidated22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.7 / 100 000WorldwideValue and classValidated25320104[PMID]_WHO World Health Organization (GLOBOCAN 2012)[OTHER]
Annual incidence1-9 / 100 0006.592 / 100 000United KingdomValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 100 0001.848 / 100 000NorwayValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 100 0001.178 / 100 000SpainValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.485 / 100 000CroatiaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 100 0001.28 / 100 000Czech RepublicValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.305 / 100 000EstoniaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 100 0001.5 / 100 000FinlandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 100 0001.681 / 100 000FranceValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 100 0001.636 / 100 000GermanyValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 100 0002.471 / 100 000IcelandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 100 0003.736 / 100 000IrelandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.947 / 100 000ItalyValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.39 / 100 000LatviaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 100 0001.235 / 100 000AustriaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 100 0003.918 / 100 000BelgiumValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.364 / 100 000BulgariaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.526 / 100 000LithuaniaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 100 0001.319 / 100 000MaltaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.315 / 100 000PolandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.829 / 100 000PortugalValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.578 / 100 000SlovakiaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.651 / 100 000SloveniaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 100 0002.612 / 100 000SwitzerlandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 100 0005.196 / 100 000NetherlandsValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]

Value is Orphadata's ValMoy: the mean estimate per 100 000 for prevalence and incidence, the number of cases or families for case reports.

6

HPO phenotypes

10 annotations · validated 2016-06-01
HPOTerm (as annotated by Orphanet)Diagnostic
Very frequent (99-80%)
HP:0100580Barrett esophagus
HP:0001864Clinodactyly of the 5th toe
HP:0011459Esophageal carcinoma
HP:0008872Feeding difficulties in infancy
HP:0002020Gastroesophageal reflux
HP:0001513Obesity
Frequent (79-30%)
HP:0100749Chest pain
HP:0012735Cough
HP:0002017Nausea and vomiting
Occasional (29-5%)
HP:0002716Lymphadenopathy

Run the differential on the 6 obligate / very frequent terms

7

Sources for this card